192 related articles for article (PubMed ID: 19015070)
21. Efficacy and toxicity of preoperative chemotherapy with docetaxel and epirubicin in locally advanced invasive breast cancer.
Kaya AO; Coskun U; Buyukberber S; Benekli M; Tekin E; Cifter C; Ozturk B; Yildiz R; Yaman E; Uner A; Yamac D
J BUON; 2010; 15(2):248-54. PubMed ID: 20658717
[TBL] [Abstract][Full Text] [Related]
22. [Induction chemotherapy with docetaxel plus cisplatin (TP regimen) followed by concurrent chemoradiotherapy with TP regimen versus cisplatin in treating locally advanced nasopharyngeal carcinoma].
Xie FY; Zou GR; Hu WH; Qi SN; Peng M; Li JS
Ai Zheng; 2009 Mar; 28(3):279-85. PubMed ID: 19619443
[TBL] [Abstract][Full Text] [Related]
23. Pegfilgrastim +/- ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer. Results from the GEPARTRIO study.
von Minckwitz G; Kümmel S; du Bois A; Eiermann W; Eidtmann H; Gerber B; Hilfrich J; Huober J; Costa SD; Jackisch C; Grasshoff ST; Vescia S; Skacel T; Loibl S; Mehta KM; Kaufmann M;
Ann Oncol; 2008 Feb; 19(2):292-8. PubMed ID: 17846019
[TBL] [Abstract][Full Text] [Related]
24. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
O'Shaughnessy JA; Denicoff AM; Venzon DJ; Danforth D; Pierce LJ; Frame JN; Bastian A; Ghosh B; Goldspiel B; Miller L
Ann Oncol; 1994 Oct; 5(8):709-16. PubMed ID: 7826903
[TBL] [Abstract][Full Text] [Related]
25. Primary chemotherapy with gemcitabine, liposomal doxorubicin and docetaxel in patients with locally advanced breast cancer: results of a phase I trial.
Schmid P; Krocker J; Schulz CO; Michniewicz K; Dieing A; Eggemann H; Heilmann V; Blohmer JU; Sezer O; Elling D; Possinger K
Anticancer Drugs; 2005 Jan; 16(1):21-9. PubMed ID: 15613900
[TBL] [Abstract][Full Text] [Related]
26. Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study.
Cardoso F; Ferreira Filho AF; Crown J; Dolci S; Paesmans M; Riva A; Di Leo A; Piccart MJ
Anticancer Res; 2001; 21(1B):789-95. PubMed ID: 11299845
[TBL] [Abstract][Full Text] [Related]
27. Feasibility and safety of dose-dense docetaxel after conventional epirubicin and cyclophosphamide as adjuvant treatment for early breast cancer patients.
Sanna G; Pestrin M; Zafarana E; Biagioni C; Cavaciocchi D; Turner N; Di Leo A; Biganzoli L
Breast; 2013 Oct; 22(5):926-32. PubMed ID: 23707082
[TBL] [Abstract][Full Text] [Related]
28. Neo-adjuvant therapy with dose-dense docetaxel plus short-term filgrastim rescue for locally advanced breast cancer.
Paciucci PA; Raptis G; Bleiweiss I; Weltz C; Lehrer D; Gurry R
Anticancer Drugs; 2002 Sep; 13(8):791-5. PubMed ID: 12394262
[TBL] [Abstract][Full Text] [Related]
29. Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC regimen) in advanced malignancies.
Wesolowski R; Peereboom D; Weiss P; Elson P; Thomas Budd G
Invest New Drugs; 2010 Aug; 28(4):502-8. PubMed ID: 19434371
[TBL] [Abstract][Full Text] [Related]
30. A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer.
Natoli C; Cianchetti E; Tinari N; Angelucci D; Grassadonia A; Zilli M; Ficorella C; Ricevuto E; Grossi S; De Tursi M; Carella C; Rispoli AI; Iacobelli S
Ann Oncol; 2007 Jun; 18(6):1015-20. PubMed ID: 17369601
[TBL] [Abstract][Full Text] [Related]
31. A Dose-Escalating Pilot Study (NCT03017404) of Pegylated Liposomal Doxorubicin and Cyclophosphamide, Followed by Docetaxel Administration as a Neoadjuvant Chemotherapy Regimen in Patients with Locally Advanced Breast Cancer.
Cheng M; Song Z; Qi Y; Wang X; Zhang L; Shi J; Wang M
Oncol Res Treat; 2019; 42(5):269-274. PubMed ID: 30943501
[TBL] [Abstract][Full Text] [Related]
32. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
Mackey JR; Pieńkowski T; Crown J; Sadeghi S; Martin M; Chan A; Saleh M; Sehdev S; Provencher L; Semiglazov V; Press MF; Sauter G; Lindsay M; Houé V; Buyse M; Drevot P; Hitier S; Bensfia S; Eiermann W
Ann Oncol; 2016 Jun; 27(6):1041-1047. PubMed ID: 26940688
[TBL] [Abstract][Full Text] [Related]
33. Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer.
Vriens BE; Aarts MJ; de Vries B; van Gastel SM; Wals J; Smilde TJ; van Warmerdam LJ; de Boer M; van Spronsen DJ; Borm GF; Tjan-Heijnen VC;
Eur J Cancer; 2013 Oct; 49(15):3102-10. PubMed ID: 23850450
[TBL] [Abstract][Full Text] [Related]
34. Phase II trial of a doxorubicin/docetaxel doublet for locally advanced and metastatic breast cancer: results from national surgical adjuvant breast and bowel project trial BP-57.
Smith RE; Anderson SJ; Lembersky BC; Brown A; Mamounas E
Clin Breast Cancer; 2004 Aug; 5(3):208-15. PubMed ID: 15335453
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer.
Ganem G; Tubiana-Hulin M; Fumoleau P; Combe M; Misset JL; Vannetzel JM; Bachelot T; De Ybarlucea LR; Lotz V; Bendahmane B; Dieras V
Ann Oncol; 2003 Nov; 14(11):1623-8. PubMed ID: 14581269
[TBL] [Abstract][Full Text] [Related]
36. Risk of Neutropenia-Related Hospitalization in Patients Who Received Colony-Stimulating Factors With Chemotherapy for Breast Cancer.
Agiro A; Ma Q; Acheson AK; Wu SJ; Patt DA; Barron JJ; Malin JL; Rosenberg A; Schilsky RL; Lyman GH
J Clin Oncol; 2016 Nov; 34(32):3872-3879. PubMed ID: 27646945
[TBL] [Abstract][Full Text] [Related]
37. Dose-dense nonpegylated liposomal Doxorubicin and docetaxel combination in breast cancer: dose-finding study.
Ricevuto E; Cocciolone V; Mancini M; Cannita K; Romano S; Bruera G; Pelliccione M; Adinolfi MI; Ciccozzi A; Bafile A; Penco M; Ficorella C
Oncologist; 2015 Feb; 20(2):109-10. PubMed ID: 25601964
[TBL] [Abstract][Full Text] [Related]
38. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
[TBL] [Abstract][Full Text] [Related]
39. Oblimersen combined with docetaxel, adriamycin and cyclophosphamide as neo-adjuvant systemic treatment in primary breast cancer: final results of a multicentric phase I study.
Rom J; von Minckwitz G; Eiermann W; Sievert M; Schlehe B; Marmé F; Schuetz F; Scharf A; Eichbaum M; Sinn HP; Kaufmann M; Sohn C; Schneeweiss A
Ann Oncol; 2008 Oct; 19(10):1698-705. PubMed ID: 18477581
[TBL] [Abstract][Full Text] [Related]
40. Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer.
Misset JL; Dieras V; Gruia G; Bourgeois H; Cvitkovic E; Kalla S; Bozec L; Beuzeboc P; Jasmin C; Aussel JP; Riva A; Azli N; Pouillart P
Ann Oncol; 1999 May; 10(5):553-60. PubMed ID: 10416005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]